Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced promising ...

Biotherapeutics announced promising preclinical results for its systemic RTNova platform. The platform has successfully delivered ...

Feb. 4, 2025 — Research has shown that a potential new targeted therapy for childhood brain cancer is effective in infiltrating and killing tumor cells in ... How Healthy Stem Cells Turn Into ...

This study shows that engineered E. coli Nissle 1917 producing indole-3-acetic acid (IAA), an AhR agonist, modulate the tumor ...

A New Way to Predict Cancer's Spread? Scientists Look at 'Stickiness' of Tumor Cells Mar. 5, 2025 — By assessing how 'sticky' tumor cells are, researchers have found a potential way to predict ...

Development strategies designed to reduce the unknowns so that cell and gene therapy innovators can develop robust processes ...

Matthew Matasar, MD, discussed what the findings from the ELM-1 trial of odronextamab in diffuse large B-cell lymphoma mean ...

LONDON, UK & CHICAGO, IL, USA I March 05, 2025 I Anova Enterprises, Inc. (Anova), a technology-enabled CRO dedicated to accelerating promising treatments, ...

Cancer recurrence prediction is inherently complex due to the interplay of genetic, environmental, and treatment-related ...

In an earlier study, patients with biomarker-positive high-grade glioma lived longer after treatment with DB107 than biomarker-negative patients.

Immorta Bio Inc, a Scientific Longevity Company dedicated to "Treating Diseases of Aging and Aging as Diseasetm" announced today filing of a patent application covering its ImmortaSometm personalized ...

T-cell receptor (TCR) therapy holds immense potential in revolutionizing cancer treatment by harnessing the power of the immune system to target and eliminate tumors. Unlike CAR-T therapy, which is ...